| Characteristic | Indicator score from 1 (lowest) to 5 (highest) |
|---|---|
| GSK plc | 3.77 |
| Novartis AG | 3.74 |
| Pfizer Inc. | 3.58 |
| AstraZeneca plc | 3.51 |
| Sanofi | 3.49 |
| Johnson & Johnson | 3.37 |
| Novo Nordisk A/S | 3.35 |
| Boehringer-Ingelheim GmbH | 3.34 |
| Merck KGaA | 3.25 |
| Bayer AG | 3.21 |
| Takeda Pharamceutical Co. | 3.17 |
| Roche Holding Ltd. | 3.03 |
| Eisai Co. Ltd. | 2.78 |
| Bristol-Myers Squibb Co. | 2.72 |
| Gilead Sciences Inc. | 2.2 |
| Astellas Pharma Inc. | 2 |
| Merck & Co. Inc. | 1.97 |
| Daiichi Sankyo Co. Ltd. | 1.85 |
| AbbVie Inc. | 1.75 |
| Eli Lilly & Co. | 1.72 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
November 2024
Worldwide
As of November 2024
The Access to Medicine Index is an independent
initiative that ranks the world’s
20 largest companies according to their
efforts to make their products more available,
affordable and accessible in developing
countries, highlighting policy and
practice that either facilitate or hinder
access to medicine.
The Index uses a framework that evaluates
company activities in seven areas of activity,
or technical areas, considered to be key to
enhancing access to medicine in developing
countries, and across four important aspects
of action, or strategic pillars.
A score of zero means lowest and five signifies highest indicator score among the company set.
